Enabling anti-tumor immunity by unleashing ILC2

• 作者: Andreas Diefenbach Irene Mattiola
• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2020,（6）
• 页码范围: 461-462
• 页数: 2页
• 语种: 英文

摘要

Group 2 innate lymphoid cells (ILC2s) are tissue-resident lymphocytes involved in type 2 immune responses to worm infections and in the pathogenesis of allergies.Balachandran and colleagues now reveal that IL33-driven expansion of ILC2 unleashes T cell-mediated tumor immunity and that therapeutic modulation of ILC2 is a promising immunotherapeutic strategy for the treatment of pancreatic cancer, in particular when combined with PD1 checkpoint blockade. The immune system is an important barrier to tumorigenesis.1 While much insights have been gainedinto harnessing the power of T cells and natural killer (NK) cells to defeat cancer, the roles of other components of the immune system, in particular those of its innate arm, are less clear.This is much warranted as some of these are important "enablers" of adaptive, antigenspecific immunity.2 Innate lymphoid cells (ILCs) are a recently discovered population of tissue-resident innate lymphocytes that are mainly found in barrier tissues and in organs associated with metabolism (i.e., liver, pancreas and adipose tissue).2 Based on distinct effector programs, three main groups of ILC can be discerned, ILC1, ILC2 and ILC3, which are striking mirror images of the three main T helper cell effector states (Th1, Th2 and Th17).3 However, there are profound and intriguing differences.